Imagine a tiny, radioactive glue that can be injected directly into a tumor. Instead of beaming radiation from outside the body and hitting healthy tissue, this 'glue' stays exactly where it is placed to kill the cancer from the inside. It acts like a precision-guided internal bomb that protects the surrounding healthy organs.
Patients with unresectable pancreatic and liver cancers have very poor prognoses and limited treatment options. Existing radiotherapy often causes significant off-target damage to healthy tissue.
A radiotherapy platform (YntraDose) including a radioactive microsphere delivery system, a customized dosimetry software for treatment planning, and a clinical study protocol for LA-PDAC.
If you are a drug developer dealing with low survival rates in pancreatic cancer — this project developed YntraDose that acts as an add-on therapy to first-line standard chemotherapy. It targets the 30% of pancreatic cancer patients with unresectable locally advanced disease.
If you are a device manufacturer dealing with the limitations of external beam radiotherapy — this project developed a percutaneous administration platform that eliminates off-target radiation doses. It simplifies the treatment process using a 4:1 mixing ratio for easier preparation.
If you are a clinic dealing with high-risk solid tumors like HCC or PDAC — this project developed a cost-effective 'radiotherapy from within' platform. It allows for personalized treatment delivered under ultrasound or CT guidance.
Based on available project data, the specific price is not mentioned, but the platform is described as being designed to be cost-effective compared to traditional radiotherapy.
The project has optimized the product preparation by simplifying the mixing process to a 4:1 ratio using a BSA chamber and WFI, which suggests a move toward standardized production.
Based on available project data, specific patent numbers are not listed, but the technology is developed by BetaGlue Therapeutics SPA as a proprietary platform called YntraDose.
BetaGlue obtained authorization in Q4 2025 to start an early feasibility study in Italy, UK, and Belgium for locally advanced pancreatic cancer.
A customized dosimetry software was released at M6 to assess treatment planning and post-treatment dosimetry for the patient.
The project is led by a single Italian SME, BetaGlue Therapeutics SPA, which holds a 100% industry ratio. This lean structure indicates a highly focused commercial drive, with the company managing all development from software release to clinical trial authorization.
Contact BetaGlue Therapeutics SPA in Italy
Contact us to explore licensing opportunities for YntraDose radiotherapy technology.
